Search research articles
Contact Us
Filters
Showing results (261-270 of 276) with videos related to
Page
of 28
Sort By:
Bioorganic & Medicinal Chemistry Letters
|
March 11, 2008
Synthesis of N-pyrimidinyl-2-phenoxyacetamides as adenosine A2A receptor antagonists
Xiaohu Zhang, Jaimie K Rueter, Yongsheng Chen, et al.
The Lancet. HIV
|
December 1, 2023
HIV pre-exposure prophylaxis and its implementation in the PrEP Impact Trial in England: a pragmatic health technology assessment
Ann K Sullivan, John Saunders, Monica Desai, et al.
Trials
|
March 26, 2016
An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxis
David I Dolling, Monica Desai, Alan McOwan, et al.
Journal of Medicinal Chemistry
|
January 15, 2008
Identification of novel, water-soluble, 2-amino-N-pyrimidin-4-yl acetamides as A2A receptor antagonists with in vivo efficacy
Deborah H Slee, Xiaohu Zhang, Manisha Moorjani, et al.
BMJ Open
|
April 2, 2020
Accelerated partner therapy (APT) partner notification for people with <i>Chlamydia trachomatis</i>: protocol for the Limiting Undetected Sexually Transmitted infections to RedUce Morbidity (LUSTRUM) APT cross-over cluster randomised controlled trial
Claudia S Estcourt, Alison R Howarth, Andrew Copas, et al.
Clinical Psychology Review
|
March 7, 2020
Screening and assessment tools for gaming disorder: A comprehensive systematic review
Daniel L King, Samuel R Chamberlain, Natacha Carragher, et al.
Journal of Medicinal Chemistry
|
March 1, 2008
2-Amino-N-pyrimidin-4-ylacetamides as A2A receptor antagonists: 1. Structure-activity relationships and optimization of heterocyclic substituents
Deborah H Slee, Yongsheng Chen, Xiaohu Zhang, et al.
Journal of Medicinal Chemistry
|
October 25, 2008
Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease
Xiaohu Zhang, John E Tellew, Zhiyong Luo, et al.
Nature Genetics
|
September 6, 2016
Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance
Maria Secrier, Xiaodun Li, Nadeera de Silva, et al.
Journal of Medicinal Chemistry
|
October 17, 2003
Design and synthesis of 4-azaindoles as inhibitors of p38 MAP kinase
Alejandra Trejo, Humberto Arzeno, Michelle Browner, et al.
Page
of 28
Search research articles
Search
Showing results (261-270 of 276) with videos related to
Sort By:
Page
of 28
Bioorganic & Medicinal Chemistry Letters
|
March 11, 2008
Synthesis of N-pyrimidinyl-2-phenoxyacetamides as adenosine A2A receptor antagonists
Xiaohu Zhang, Jaimie K Rueter, Yongsheng Chen, et al.
The Lancet. HIV
|
December 1, 2023
HIV pre-exposure prophylaxis and its implementation in the PrEP Impact Trial in England: a pragmatic health technology assessment
Ann K Sullivan, John Saunders, Monica Desai, et al.
Trials
|
March 26, 2016
An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxis
David I Dolling, Monica Desai, Alan McOwan, et al.
Journal of Medicinal Chemistry
|
January 15, 2008
Identification of novel, water-soluble, 2-amino-N-pyrimidin-4-yl acetamides as A2A receptor antagonists with in vivo efficacy
Deborah H Slee, Xiaohu Zhang, Manisha Moorjani, et al.
BMJ Open
|
April 2, 2020
Accelerated partner therapy (APT) partner notification for people with <i>Chlamydia trachomatis</i>: protocol for the Limiting Undetected Sexually Transmitted infections to RedUce Morbidity (LUSTRUM) APT cross-over cluster randomised controlled trial
Claudia S Estcourt, Alison R Howarth, Andrew Copas, et al.
Clinical Psychology Review
|
March 7, 2020
Screening and assessment tools for gaming disorder: A comprehensive systematic review
Daniel L King, Samuel R Chamberlain, Natacha Carragher, et al.
Journal of Medicinal Chemistry
|
March 1, 2008
2-Amino-N-pyrimidin-4-ylacetamides as A2A receptor antagonists: 1. Structure-activity relationships and optimization of heterocyclic substituents
Deborah H Slee, Yongsheng Chen, Xiaohu Zhang, et al.
Journal of Medicinal Chemistry
|
October 25, 2008
Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease
Xiaohu Zhang, John E Tellew, Zhiyong Luo, et al.
Nature Genetics
|
September 6, 2016
Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance
Maria Secrier, Xiaodun Li, Nadeera de Silva, et al.
Journal of Medicinal Chemistry
|
October 17, 2003
Design and synthesis of 4-azaindoles as inhibitors of p38 MAP kinase
Alejandra Trejo, Humberto Arzeno, Michelle Browner, et al.
Page
of 28